DOI : 10.1055/s-00000059

Pneumologie

Issue S 01 · Volume 70 · February 2016 DOI: 10.1055/s-006-30929


57. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
Leipzig, 2.–5. 3. 2016

Kongresspräsident: Prof. Dr. med. Hubert Wirtz, Leipzig – Kongresssekretär: Dr. med. Jens Bräunlich, Leipzig

P514
P490
Dickgreber, N; Yang, JCH; Ahn, MJ; Halmos, B; Hirsh, V; Hochmair, M; Levy, B; de Marinis, F; Mok, T; O'Byrne, K; Okamoto, I; Schuler, M; Sebastian, M; Shah, R; Tan, EH; Yamamoto, N; Märten, A; Massey, D; Wind, S; Carbone, D: Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
P132
Griesinger, F; Lüers, A; Falk, M; Conradi, I; Reinhardt, M; Kluge, A; Willborn, K; Prenzel, R; Scriba, DC; Henke, R; Eberhardt, W; Hallas, C; Tiemann, M: Intercalated TKI and chemotherapy induction in EGFR mt+ NSCLC stage IIIA and IIIB: report of 3 cases with complete pathologic remission in mediastinal lymph nodes
P233
Griesinger, F; Sebastian, M; Serke, M; Grohé, C; Hillejan, L; Passlick, B; Reinmuth, N; Graeven, U; Radke, S; Karatas, A; Tiemann, M; Overbeck, T: Induction therapy with intercalated TKI and chemotherapy in NSCLC with activating EGFR mutation in stages II-IIIB: NeoIntercal
P30
Falkenstern-Ge, R; Kimmich, M; Wohlleber, M; Friedel, G; Bode, S; Ott, G; Kohlhäufl, M: Nivolumab-induzierte rasche Tumorremission
P261
Schmidtke-Schrezenmeier, G; Rüdiger, S; Gagiannis, D; Rottbauer, W; Kropf-Sanchen, C: Schwere Pneumonitis bei einem Patienten mit Plattenepithelkarzinom der Lunge bereits nach 2–maliger Gabe von Nivolumab
P5
Kohlhäufl, M; Falkenstern-Ge, R; Kimmich, M; Wohlleber, M; Friedel, G; Kalla, C; Ott, G: Crizotinib-induzierte rasche Tumorremission bei zwei Patientinnen
P79
Pawel, J von; Kraff, S; Fischer, JR; Eberhardt, W; Gauler, T; Müller, L; Reinmuth, N; Reck, M; Kimmich, M; Mayer, F; Kopp, HG; Behringer, DM; Ko, YD; Frueh, M; Hilger, RA; Roessler, M; Moritz, B; Jaehde, U; Joerger, M: Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced Non-Small Cell Lung Cancer (NSCLC) patient
P532